Allogeneic stem cell transplantation for myelodysplastic syndrome

Seminars in Hematology
A John Barrett, Bipin N Savani

Abstract

Although it is only used to treat a minority of patients with myelodysplastic syndromes, stem cell transplantation (SCT) is the only proven curative treatment for this condition. Because MDS occurs in a population of older adults with significant comorbidities, reduced-intensity conditioning (RIC) regimens have been particularly important in extending safe SCT to the large MDS population over the age of 60 years. Extension of the unrelated donor pool together with the introduction of umbilical cord blood transplants in adults has extended the number of patients with suitable donors. Nevertheless overall mortality from SCT is greater than 50% because of relapse and non-relapse mortality (NRM). New developments to improve outcome include the tailoring of the transplant approach to the individual based on age and comorbidity, and the use of pretransplant chemotherapy to reduce disease bulk prior to transplant, as well as the introduction of post-transplant immunotherapy (pre-emptive donor lymphocyte infusions) and chemotherapy to prevent relapse. Further improvements in transplant outcome await better ways to reconstitute immunity and amplify the graft-versus-leukemia (GVL) effect without causing graft-versus-host disease (GVHD), ...Continue Reading

References

Mar 22, 2001·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·S ShiobaraY Kodera
May 31, 2002·Blood·Philippe GuardiolaUNKNOWN Subcommittee for Myelodysplastic Syndromes of the Chronic Leukaemia Working Group of the European Blood and Marrow Transplan
Oct 18, 2002·Blood·José A Pérez-SimónUNKNOWN Spanish and United Kingdom Collaborative Groups for Nonmyeloablative Transplantation
Nov 25, 2003·Hematology·A John BarrettNelson Chao
Oct 21, 2004·Best Practice & Research. Clinical Haematology·John McCarty
Dec 31, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Bart L ScottH Joachim Deeg
Feb 1, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Raymond WongSergio Giralt
Apr 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Herschel WallenAjay K Gopal
Jul 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Koen van BesienW Stock
Jul 26, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Scott R SolomonA John Barrett
Sep 27, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Vikas GuptaThomas Kiss
Sep 28, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca MalcovatiMario Cazzola
Jan 28, 2006·Mayo Clinic Proceedings·David P Steensma, John M Bennett
Apr 7, 2006·Blood·Rodrigo MartinoUNKNOWN Myelodysplastic Syndrome subcommittee of the Chronic Leukemia Working Party of the European Blood and Marrow Transplantation
Jun 9, 2006·Blood Reviews·Wendy IngramGhulam J Mufti
Nov 25, 2006·Hematology·Charles A Schiffer
Jan 27, 2007·Current Opinion in Hematology·Claudio G BrunsteinJohn E Wagner

❮ Previous
Next ❯

Citations

Jan 1, 2008·Current Hematologic Malignancy Reports·A John Barrett, Elaine M Sloand
Jan 27, 2009·Bone Marrow Transplantation·A GratwohlUNKNOWN European Group for Blood and Marrow Transplantation
Apr 12, 2011·Bone Marrow Transplantation·I DanyleskoA Nagler
Dec 5, 2012·Bone Marrow Transplantation·R MartinoUNKNOWN Acute Leukemia Working Party the subcommittee for Myelodysplastic Syndromes of the Chronic Malignancies Working Party of the
Feb 11, 2014·Best Practice & Research. Clinical Haematology·Uwe Platzbecker, Ghulam Mufti
Jan 19, 2010·Der Internist·C AulU Germing
Feb 6, 2009·American Journal of Hematology·Margaret T Kasner, Selina M Luger
Jun 29, 2012·The American Journal of Medicine·Roger M Lyons
Jun 24, 2008·Expert Opinion on Pharmacotherapy·Sridhar Srinivasan, Charles A Schiffer
Aug 6, 2011·Clinical Lymphoma, Myeloma & Leukemia·Ali Al-AmeriAlfonso Quintás-Cardama
Oct 27, 2009·Bone Marrow Transplantation·B N SavaniK Rezvani
Jun 24, 2017·Frontiers in Immunology·Anne M DickinsonHans Jochem-Kolb
Oct 18, 2008·Cancer Control : Journal of the Moffitt Cancer Center·Ghulam J Mufti, Tara L Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.